GEN Exclusives

More »

GEN News Highlights

More »
Jan 23, 2012

EntreMed Raises $10M To Progress Clinical Anticancer Pipeline and Expand R&D

  • EntreMed raised $10 million through the issuance of convertible notes to accredited investors. The firm says it will use the proceeds, estimated at about $9.3 million net, to expand its R&D activities, fund new clinical trials, and initiate new initiatives and long-term strategic plans.

    EntreMed is a clinical-stage pharmaceutical company focused on the treatment of cancer and inflammatory diseases. The firm’s oral oncology candidates are designed to inhibit multiple pathways that promote the formation and replication of tumor cells, while interrupting the formation of tumor-feeding blood vessels.

    Lead candidate ENMD-2076 is an orally active Aurora A/angiogenic kinase inhibitor, which has completed Phase I studies in patients with solid tumors and leukemia, and is currently undergoing Phase II evaluation in ovarian cancer, and Phase I testing against multiple myeloma. Positive progression-free survival data from a Phase II study evaluating ENMD-2076 monotherapy in patients with platinum-resistant ovarian cancer was reported in October 2011. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?